Home » Resources 

Resources

Explore our media section to discover insightful videos, informative podcasts, and engaging articles showcasing the innovative applications and advancements in cell testing technology.

Filtres
Document PDF
Document PDF
Posters
Gene editing on primary & stem cells using LentiFlash (FlashRNA®) RNA delivery approach (ASGCT 2022)
Document PDF
Document PDF
Posters
NK cells engineering using advanced Lentiviral Vectors quality and design (EBMT 2023)
Flash BioSolutions obtains Pharmaceutical Establishment status, opening up new avenues for its revolutionary FlashRNA® technology
Document PDF
Document PDF
Press releases
Flash BioSolutions obtains Pharmaceutical Establishment status, opening up new avenues for its revolutionary FlashRNA® technology
The company's recent achievement highlights their dedication to delivering high-quality innovative therapies. They are particularly proud of their revolutionary RNA technology...
KIRAGEN Bio & Flash BioSolutions announce innovative partnership to revolutionize CAR-T Therapies for solid tumors
Document PDF
Document PDF
Press releases
KIRAGEN Bio & Flash BioSolutions announce innovative partnership to revolutionize CAR-T Therapies for solid tumors
The company's recent achievement highlights their dedication to delivering high-quality innovative therapies.
Introducing Flash BioSolutions : Spearheading advancements in Biopharmaceutical CDMO sector
Document PDF
Document PDF
Press releases
Introducing Flash BioSolutions : Spearheading advancements in Biopharmaceutical CDMO sector
Flash BioSolutions® strengthens its position in the Contract Development and Manufacturing Organisation (CDMO) market in the biopharmaceutical sector with a dynamic rebranding.
Document PDF
Document PDF
Posters
GMP platform for lentiviral vector production with 9000 batches produced (Advanced Therapies 2023)
Appointment of Jérôme Bédier as Président to accelerate its biopharmaceutical CDMO business development
Document PDF
Document PDF
Press releases
Appointment of Jérôme Bédier as Président to accelerate its biopharmaceutical CDMO business development
The company thus intends to accelerate its development strategy and reinforce its position as an expert in the bioproduction of high-purity, high-concentration DNA and RNA lentiviral solutions for the biopharmaceutical industry.
Document PDF
Document PDF
Posters
Lentivirus Manufacturing : successful & reproducible continuum process from research batches to clinical application (ISCT 2023)
Document PDF
Document PDF
Posters
Next Generation Therapy : RNA delivery by LentiFlash (FlashRNA®) for an efficient CRISPR/Cas9-mediated gene knockout in Human iPS (EBMT 2023)
Document PDF
Document PDF
Posters
Efficient & safe delivery of multiple mRNA using non-integrative bacteriophage-chimeric retrovirus-like particles for in vivo application (ASGCT 2022)
Document PDF
Document PDF
Posters
All-in-one delivery using LentiFlash (FlashRNA®) for clinical application (ESGCT 2019)
Document PDF
Document PDF
Posters
All-in-one Delivery Using LentiFlash® technology, a MS2-chimeric RNA Delivery Tool Designed for Clinical Applications (ASGCT 2019)

FAQ

Explore our media section to discover insightful videos, informative podcasts, and engaging articles showcasing the innovative applications and advancements in cell testing technology.

How do Flash BioSolutions lentiviral vectors differ to those from other providers?

Flash BioSolutions has developed a proprietary purification & concentration process for lentiviral vectors production. Purification levels are tailored to your application.

Flash BioSolutions generates high titer and highly pure lentiviral particles that guarantee cell viability and phenotype. Our technical experts are dedicated to the success of your project, from cassette design to transduction protocols.

What are the differences between AAV and Lentiviral vectors?

Each method has both advantages and drawbacks for specific applications, depending on its technical characteristics. For example, the use of AAVs for the transfer of genetic material is limited by the length of the sequence of interest and by the pseudotype; non-viral methods can be problematic for the study of gene expression in primary cells because of cell toxicity and/or lower efficiency.

CONTACT US

We invite you to reach out to us for any inquiries regarding our services, technical support, or potential collaborations.

Please complete the following form, and a member of our team will respond promptly.

+33(0) 5 61 28 70 75